Clinical Trial Challenges and Potential Solutions: Addressing Non-Superiority and Regulatory Hurdles

The clinical trial in question faces a significant challenge: its results are not satisfactory. Our review of the clinical data submitted to the FDA reveals that the non-superiority hypothesis was not established. With a non-inferior value of 15% and a point value of 18%, the likelihood of trial failure is high. This is likely a key reason why the FDA has yet to grant approval.

The situation is further complicated by the NMPA's even stricter review process compared to the FDA's, making approval from this regulatory body even more challenging. While exceptions exist, such as the case of the Impella left cardiac assist system, these are rare. In the Impella case, despite the trial's initial failure, subgroup analysis revealed effectiveness within a specific group. Furthermore, extending the trial period from 30 to 90 days demonstrated efficacy, ultimately leading to FDA approval.

Given these factors, we strongly recommend a thorough re-analysis of the clinical trial data. This could uncover potential areas for improvement and strengthen the case for regulatory approval. Analyzing data from different perspectives, such as exploring subgroup effects or considering alternative endpoints, might yield valuable insights that could increase the likelihood of success. Remember, while challenges exist, a rigorous and thorough approach to data analysis can potentially illuminate a path forward.